ReviewFrontiers in cellular and infection microbiology2025
Treatment of xerostomia in Sjögren's syndrome - what effect does it have on the oral microbiome?
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Photobiomodulation for salivary gland dysfunction: aligning clinical expectations with etiology-dependent treatment responsiveness.Lasers in medical science · 2026Review
- Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database.Journal of thoracic disease · 2026Article
- Causal Relationships Between the Oral Microbiome and Autoimmune Diseases: A Mendelian Randomization Study.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's syndrome is an autoimmune disease characterized by lymphatic infiltration of secretory tissues. The disease results in dryness of the eyeball or mouth, which often occur simultaneously. Agents used to treat Sjögren's syndrome may improve oral hydration and the patient's quality of life. There are several pharmacological and non-pharmacological agents used to treat significant problem like xerostomia. The use of appropriate medicines (i.e. pilocarpine and cevimeline) may cause changes in the local microbiome, which is very sensitive to quantitative changes in water. As a result of Sjögren's syndrome, a new balance of the microbiome is established in the oral cavity, which, if disturbed by medical measures, may increase the risk of oral lesions (such as periodontopathies or caries) or reduce this risk. Overall, the knowledge regarding microbiological aspects and agents treating oral dryness is still not well described but initial results indicate some microbial alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.